Clinical trials: Stereotactic Ablative Radiotherapy
Abdominal Cancer, Lung Cancer
A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)
To determine if the investigators are able to deliver highly focused, intense radiation to tumours in the abdominal region or chest cavity whilst limiting the dose to surrounding organs using a high field strength MR-Linac.
- Trial name
- MIDSECTION (NCT05903430)
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- The Christie NHS Foundation Trust
Cardiac Arrhythmia
StereoTactic Ablative RadioTherapy of Cardiac Arrhythmias
This is a prospective, single-center, phase II trial that will be monitoring the safety and efficacy of using stereotactic ablative radiotherapy (SBRT) to treat patients with a medical condition affecting heart rate and rhythm…
- Trial name
- START-CA (NCT04843683)
- Testing
- Stereotactic Ablative Radiotherapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University Health Network, Toronto
Lung Cancer
Effect on Patient Reported Outcomes of VATS and SABR (LILAC)
This study will monitor the effect on patients reported outcomes (PROMs) of VATS resection and SABR for NSCLC delivered at the Leeds Cancer Centre The investigator will support with this information the Shared Decision Making…
- Trial name
- LILAC (NCT02882750)
- Testing
- EORTC QLQ-C30 (version 3.0)., PS Q18, Decision Self-Efficacy Scale
- Volunteers
- 244 people
- Sponsor
- University of Leeds
Unresectable Solid Tumor, Metastatic Cancer
Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy
Spatially fractionated radiotherapy (SFRT or GRID) addresses some limitations of traditional stereotactic body radiation therapy by relying on beam collimation to create high-dose "peaks" and intervening low-dose "valleys"…
- Trial name
- NCT05831579
- Testing
- Proton GRID Radiotherapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
NSCLC Stage IV, Metastatic Disease
IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study
This will be a phase II trial testing if the combination of stereotactic ablative body radiotherapy (SABR) and L19-IL2 improve the progression-free survival in patients with limited metastatic non-small cell lung cancer (NSCLC).
- Trial name
- IMMUNOSABR2 (NCT03705403)
- Testing
- Darleukin, Radiation
- Where
- 15 sites in Belgium, France and 4 more
- Volunteers
- 88 people
- Sponsor
- Maastricht University Medical Center
Renal Cancers
Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer
The goal of this phase II clinical trial is to evaluate the efficacy of the completely non-invasive treatment option of stereotactic radiation therapy for the treatment of biopsy proven and growing small renal tumors.
- Trial name
- NCT02141919
- Testing
- Stereotactic Ablative Radiation Therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Texas Southwestern Medical Center
Oligoprogressive, Castration-Resistant Prostate Cancer
Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer
There is increasing worldwide interest in exploring stereotactic ablative body radiotherapy (SABR) for treating metastases in men with prostate cancer, including for the treatment of oligoprogressive metastases.
- Trial name
- NCT04838899
- Testing
- Stereotactic Body Radiation Therapy (SABR)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
Breast Cancer, Metastases
SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors
The study is being done to determine if stereotactic ablative radiotherapy (SABR) can control tumour growth for patients with metastatic breast cancer.
- Trial name
- SABR PRIMER (NCT06937281)
- Testing
- SABR
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
SABR Including Regional Lymph Node Irradiation for Patients With High Risk Prostate Cancer (SATURN)
Current treatment options for high risk localized prostate cancer include radical prostatectomy +/- postoperative radiotherapy, radical radiotherapy with androgen deprivation therapy.
- Trial name
- SATURN (NCT01953055)
- Testing
- Stereotactic ablative radiotherapy
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
NSCLC/Oligometastatic Cancer (Single Lung Lesion)
'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung)
This is a phase II, non-randomised study examining the safety of treating high risk centrally located non-small cell lung cancer (NSCLC) tumours and single pulmonary oligometastatic lesions using radiation therapy (RT), for…
- Trial name
- SOURCE Lung (NCT04375904)
- Testing
- Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR)
- Where
- 2 sites in Ireland
- Volunteers
- 68 people
- Sponsor
- Cancer Trials Ireland
Non-small Cell Lung Cancer (NSCLC)
Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)
A research study of a procedure to treating lung cancer with focused radiation called Stereotactic Ablative Radiotherapy (SABR).
- Trial name
- NCT01463423
- Testing
- iSABR, 25 Gray in 1 fraction for small peripheral tumors, iSABR, 50 Gray in 4 fractions for medium peripheral tumors, iSABR, 54 Gray in 3 fractions for large peripheral tumors
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 256 people
- Sponsor
- Stanford University
Uterine Cervical Neoplasm
Cervical Boost by Ablative Stereotactic Radiotherapy (SABR) vs Brachytherapy in Patients With Cervical Carcinoma
Background Cervical cancer (CaCu) is the fourth cause of death in women. In patients with locally advanced disease, the treatment of choice is CT/RT, followed by additional boosting with brachytherapy (BT).
- Trial name
- SABRVICAL (NCT06560697)
- Testing
- SABR VS Intracavitary 3D Brachytherapy
- Where
- Mexico
- Volunteers
- 84 people
- Sponsor
- National Institute of Cancerología
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Risk Adapted SABR(SABR) in Stage I NSCLC And Lung Metastases
This study is designed to evaluate the safety of Stereotactic Ablative Radiotherapy (SBRT) in selected patients with stage I Non Small Cell Lung Cancer (NSCLC) or metastatic lung cancer to demonstrate the feasibility and risks of…
- Trial name
- sbrtlungfff (NCT01823003)
- Testing
- 34 Gy in a single fraction, 54Gy 18Gy/fr. x 3 fractions, 60Gy (12 x 5 fr.s)
- Where
- Spain
- Volunteers
- 67 people
- Sponsor
- Institut Català d'Oncologia
Colorectal Cancer
The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer
This is a prospective, single-center, single-arm phase II clinical trial. This study aims to evaluate the safety and tolerability of stereotactic ablative radiotherapy (SABR) in combination with Sintilimab, and to examine the…
- Trial name
- NCT04535024
- Testing
- Stereotactic Ablative Radiotherapy (SABR), Sintilimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Non-small Cell Lung Cancer
Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma
This investigator driven Phase Ib study will examine the safety, efficacy and biological effects of two schedules of pembrolizumab, an antibody targeted against anti-programmed cell death 1 (PD-1), which will be given either…
- Trial name
- SABRseq (NCT03307759)
- Testing
- Pembrolizumab, Radiotherapy (SABR)
- Where
- Australia
- Volunteers
- 13 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Oligometastatic Disease, Bone Metastases
Bony M - Stereotactic Ablative Radiotherapy (SABR) of Bony Metastases in Patients With Oligometastatic Disease
This is a prospective, investigator-initiated, phase II, multicentre-study, investigating the efficacy and toxicity of definitive SABR of osseous oligometastases, when pragmatically introduced into a daily clinical setting.
- Conditions
- Oligometastatic Disease, Bone Metastases, Stereotactic Body Radiotherapy
- Trial name
- NCT05101824
- Testing
- SABR
- Where
- 6 sites in Denmark, Norway
- Volunteers
- 67 people
- Sponsor
- Gitte Fredberg Persson MD PhD
Hepatocellular Carcinoma
Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm
The standard treatment for hepatocellular carcinoma (HCC) is surgery, such as, by hepatic resection or liver transplantation, but less than 20% of HCC patients are suitable for surgery.
- Trial name
- NCT01825824
- Testing
- Stereotactic ablative radiotherapy
- Where
- 7 sites in South Korea
- Volunteers
- 54 people
- Sponsor
- Korea Cancer Center Hospital
Recurrent Non-small Cell Lung Cancer
IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung Tumors
This phase I trial studies the side effects and best dose of stereotactic body radiation therapy when given together with ablation therapy in treating patients with non-small cell lung cancer or lung metastases.
- Trial name
- NCT01746810
- Testing
- Stereotactic body RT and IRGA
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- New Mexico Cancer Research Alliance
Sarcoma, Soft Tissue
Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma
This is a pilot study determining the feasibility of combination treatments, pembrolizumab and stereotactic ablative radiotherapy (SBRT) in subjects with soft-tissue sarcoma.
- Trial name
- NCT05488366
- Testing
- Pembrolizumab, Radiation therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, Irvine
Oligometastatic Clear Cell Renal Cell Carcinoma
SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma
This is a phase II clinical trial testing whether a combination of stereotactic ablative radiotherapy (SABR), axitinib, and toripalimab is effective and safe for treating oligometastatic clear cell renal cell carcinoma (a type of…
- Trial name
- NCT07744932
- Testing
- axitinib plus toripalimab, SABR
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Hebei Medical University Fourth Hospital